The European Medicines Agency is this week deciding whether to recommend pan-EU marketing approval for eight new drugs including luspatercept, Bristol-Myers Squibb Co. and Acceleron Pharma’s treatment for myelodysplastic syndromes (MSD) and beta-thalassemia that this month secured a second key approval in the US.
Luspatercept last November became the first US Food and Drug Administration-approved treatment for anemia in beta thalassemia (US brand name...








